MoonLake Immunotherapeutics (MLTX) News Today $48.83 -3.67 (-6.99%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Promising Outlook for MoonLake’s Sonelokimab in Psoriatic Arthritis TreatmentNovember 15 at 4:33 AM | markets.businessinsider.comMoonLake Immunotherapeutics’ Promising Phase 3 Trials for PsA Treatment Drives Buy RatingNovember 15 at 4:33 AM | markets.businessinsider.comBuy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Advancements and Strong Market PotentialNovember 14 at 11:36 AM | markets.businessinsider.comMoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday.November 14 at 8:57 AM | marketbeat.comMoonLake Immunotherapeutics announces first patients screened in IZAR programNovember 14 at 1:13 AM | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)November 14 at 1:13 AM | markets.businessinsider.comBuy Rating for MoonLake Immunotherapeutics Driven by Clinical Advancements and Market OpportunitiesNovember 11, 2024 | markets.businessinsider.comStrategic Initiatives and Financial Stability Propel MoonLake Immunotherapeutics Towards Promising Market PositionNovember 9, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Reports Q3 2024 Financial ResultsNovember 9, 2024 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Friday.November 8, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Announces Earnings ResultsMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same quarter in the prior year, the firm posted ($0.18) earnings per share.November 8, 2024 | marketbeat.comMoonLake Immunotherapeutics: Strategic Growth and Financial Stability Drive Buy RatingNovember 7, 2024 | markets.businessinsider.comPromising Growth Prospects for MoonLake Immunotherapeutics: Buy Rating Supported by Strategic Developments in HS and PsA ProgramsNovember 7, 2024 | markets.businessinsider.comBrokers Set Expectations for MLTX Q3 EarningsMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities researchers at Wedbush issued their Q3 2024 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Monday, November 4th. Wedbush analyst Y. Zhong anticipates thatNovember 7, 2024 | marketbeat.comPromising Results for MoonLake’s Sonelokimab in HS Treatment Drive Buy RatingNovember 6, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics assumed with an Outperform at WedbushNovember 6, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Wedbush to Strong-Buy RatingWedbush upgraded MoonLake Immunotherapeutics to a "strong-buy" rating in a report on Monday.November 6, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)Wedbush reaffirmed an "outperform" rating and set a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday.November 5, 2024 | marketbeat.com14,000 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by AlphaCentric Advisors LLCAlphaCentric Advisors LLC purchased a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 14,000 shares of the company'sNovember 5, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Harbor Capital Advisors Inc.Harbor Capital Advisors Inc. increased its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 100.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,468 shares of the compNovember 4, 2024 | marketbeat.comRice Hall James & Associates LLC Makes New Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX)Rice Hall James & Associates LLC purchased a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 75,469 shares of the company's stock,November 2, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Moderate Buy" by BrokeragesMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on theOctober 29, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Tuesday.October 15, 2024 | marketbeat.comMoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A HoldOctober 13, 2024 | seekingalpha.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down on Insider SellingMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down After Insider SellingOctober 9, 2024 | marketbeat.comBiotechnology Value Fund L.P. Reduces Stake in MoonLake ImmunotherapeuticsOctober 9, 2024 | finance.yahoo.comInsider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) Director Sells 171,000 Shares of StockOctober 9, 2024 | insidertrades.comMillennium Management LLC Boosts Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)Millennium Management LLC increased its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 596.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 216,October 9, 2024 | marketbeat.comMoonLake (NASDAQ:MLTX) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 8.3% - Time to Sell?MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 8.3% - Here's WhyOctober 7, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Has $5.02 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)The Manufacturers Life Insurance Company grew its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 37.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 114,234 shares of the company's stockOctober 7, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Marshall Wace LLPMarshall Wace LLP increased its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 115.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,098,630 shares of the company's stock after purchasingSeptember 26, 2024 | marketbeat.comIs MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?September 25, 2024 | msn.comLogos Global Management LP Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Logos Global Management LP acquired a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 750,000 shares of thSeptember 24, 2024 | marketbeat.comMoonLake Immunotherapeutics' (MLTX) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of MoonLake Immunotherapeutics in a research note on Monday.September 23, 2024 | marketbeat.comIntegral Health Asset Management LLC Has $9.67 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)Integral Health Asset Management LLC decreased its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 47.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2September 23, 2024 | marketbeat.comMoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR StockSeptember 23, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Progyny (PGNY) and MoonLake Immunotherapeutics (MLTX)September 20, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 5.6%MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 5.6%September 18, 2024 | marketbeat.comOppenheimer Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)September 16, 2024 | markets.businessinsider.comVictory Capital Management Inc. Acquires 24,037 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Victory Capital Management Inc. raised its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 16.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 174,682 shares of the cSeptember 16, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Position Increased by Federated Hermes Inc.Federated Hermes Inc. increased its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 2.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,128,428 shares of the company's stSeptember 15, 2024 | marketbeat.comBuy Rating on MoonLake Immunotherapeutics: Promising SLK Clinical Programs and Market Growth PotentialSeptember 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Hidradenitis Suppurativa Treatment ProspectsSeptember 13, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics: A Strong Buy on Promising Clinical Progress and Blockbuster Market PotentialSeptember 13, 2024 | markets.businessinsider.comBarclays Sticks to Their Hold Rating for MoonLake Immunotherapeutics (MLTX)September 12, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $62.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday.September 12, 2024 | marketbeat.comMoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11September 9, 2024 | finanznachrichten.deCantor Fitzgerald Reiterates Overweight Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)Cantor Fitzgerald reiterated an "overweight" rating on shares of MoonLake Immunotherapeutics in a report on Monday.September 9, 2024 | marketbeat.comMoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11September 9, 2024 | globenewswire.com Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov MLTX Media Mentions By Week MLTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼0.550.55▲Average Medical News Sentiment MLTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼93▲MLTX Articles Average Week Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CIFR News Today DCGO News Today QSI News Today CHMI News Today BREZ News Today VINC News Today CERE News Today PCVX News Today RDY News Today SRPT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLTX Stock Alerts